Assetmark Inc. Acquires 71,496 Shares of Takeda Pharmaceutical Co. $TAK

Assetmark Inc. increased its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 45.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 227,616 shares of the company’s stock after purchasing an additional 71,496 shares during the quarter. Assetmark Inc.’s holdings in Takeda Pharmaceutical were worth $4,215,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TAK. Private Trust Co. NA grew its holdings in Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the last quarter. Parkside Financial Bank & Trust lifted its stake in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the last quarter. SHP Wealth Management bought a new stake in Takeda Pharmaceutical in the fourth quarter worth about $42,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after buying an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $16.86 on Thursday. The company has a current ratio of 1.09, a quick ratio of 0.60 and a debt-to-equity ratio of 0.59. The firm has a market cap of $54.00 billion, a PE ratio of 43.22 and a beta of -0.07. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The stock has a fifty day moving average price of $16.16 and a 200-day moving average price of $17.01.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%.The company had revenue of $6.90 billion for the quarter. Equities research analysts predict that Takeda Pharmaceutical Co. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TAK shares. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, June 23rd. Zacks Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.